myelodysplastic syndromes (MDS) | Page 4 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.

Author(s): 
Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD
Primary Author: 
Zeidan AM
Journal Title: 
Cancer
Original Publication Date: 
Jul 2017

Hypomethylating agents (HMAs) have changed the landscape of the management of patients with higher-risk

Bone Marrow Diseases: 

Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints

Author(s): 
Hidalgo-López JE, Kanagal-Shamanna R, Quesada AE, Thakral B, Hu Z, Mitsuhashi T, Yabe M, Garcia-Manero G, Bueso-Ramos CE
Primary Author: 
Hidalgo-López JE
Journal Title: 
Clin Lymphoma Myeloma Leuk
Original Publication Date: 
Jul 2017

BACKGROUND:

Bone Marrow Diseases: 

First-line Therapeutic Strategies for Myelodysplastic Syndromes.

Author(s): 
Santini V
Primary Author: 
Santini V
Journal Title: 
Clin Lymphoma Myeloma Leuk
Original Publication Date: 
Jul 2017

The precise diagnostic tests and subsequent prognostic stratification for patients with myelodysplastic syndrome (MDS) are often cumbersome, yet they are the basis of successful therapy. Diverse treatment options are available for these patients; however, the decisions in real-life are often not grounded on the available evidence. Although the

Bone Marrow Diseases: 

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes

Author(s): 
Unnikrishnan A, Papaemmanuil E, Beck D, Deshpande NP, Verma A, Kumari A, Woll PS, Richards LA, Knezevic K, Chandrakanthan V, Thoms JAI, Tursky ML, Huang Y, Ali Z, Olivier J, Galbraith S, Kulasekararaj AG, Tobiasson M, Karimi M, Pellagatti A, Wilson SR
Primary Author: 
Unnikrishnan A
Journal Title: 
Cell Rep
Original Publication Date: 
Jul 2017

Bone Marrow Diseases: 

Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes

Author(s): 
Press KR, Uy N, Keefer J, Gore SD, Carraway HE, Sakoian S, Prebet T
Primary Author: 
Press KR
Journal Title: 
Leuk Lymphoma
Original Publication Date: 
Jul 2017

No abstract available.

Bone Marrow Diseases: 

Shauna McMillan - Alaskan Goes Home for Treatment & a Fresh Start

Person's Name: 
Shauna McMillan

I tell people I'm unique - almost one of a kind. I am 40 years old and have recently been diagnosed with a rare type of MDS having an unusual deletion 12q cytogenetic abnormality, known MDS 12q (-), or MDS 12q minus.  I was diagnosed in February of 2015 at age 38, however my health struggles began several years before that.
         

Bone Marrow Diseases: 

Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML

Author(s): 
Herold S, Sockel K, Sayehli C, Herbst R, Dührsen U, Oelschlägel U, Böttner A, Hindahl H, Kullmer J, Helas S, Sauer M, Mohr B, Mies A, Bornhäuser M, Ehninger G, Röllig C, Thiede C, Platzbecker U
Primary Author: 
Herold S
Journal Title: 
Leukemia
Original Publication Date: 
Jul 2017

No abstract available.

Bone Marrow Diseases: 

Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy

Author(s): 
Fenaux P, Muus P, Kantarjian H, Lyons RM, Larson RA, Sekeres MA, Becker PS, Orejudos A, Franklin J
Primary Author: 
Fenaux P
Journal Title: 
Br J Haematol
Original Publication Date: 
Jun 2017

Romiplostim can improve

Bone Marrow Diseases: